Swiss Biotech Insight Event

World CB & CDx Boston 2025

ASGCT 28th Annual Meeting

As you aim to hit your next milestone in cell and gene therapy development, Labcorp is here to collaborate and provide the critical insights you need to accelerate your progress. From discovery through clinical trials and long-term follow-up, we offer a comprehensive suite of testing solutions that span the entire development continuum.

Labcorp Publishes 2024 Corporate Responsibility Report

2025 ASCO® Annual Meeting

Expert answers for medical device safety testing questions: Using a comparative product as a control in the implant instead of HDPE or saline

Expert answers for medical device safety testing questions: Oxidized Surgical Tool Remediation

“I completed testing recently for cytotoxicity, intracutaneous irritation and Kligman maximization sensitization. My device is a limited-contact surgical tool primarily made of stainless steel. In the saline extracts, red/brown discoloration on the device and the same colored particulates in the extract were seen. I presume this is rust but want your input on what we can do next to determine the source of the rust and why it would happen if the device is made of stainless steel.”

Eight tips to eating healthy on a budget to lower financial stress

A recent International Food Information Council (IFIC) survey examined how Americans prioritize and perceive healthy eating. Nearly 60% of respondents named exercising and eating a balanced diet including fruit and vegetables among the top actions necessary for maintaining good health. Spending time to meal plan and meal prep were also reported as essential components in efforts to eat healthy food. Whether we make a plan or not, this begs the question: What causes us to buy the types of food we do?

Labcorp Declares Quarterly Dividend

BURLINGTON, N.C. , April 10, 2025 /PRNewswire/ --  Labcorp Holdings Inc.  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.

Enabling gene therapy access: Labcorp's first cell-based companion diagnostic (CDx)

The emergence of novel gene therapies has necessitated the development of cell-based CDx assays, posing multiple technical and operational challenges. Labcorp worked with a sponsor to develop the nAbCyte™ CDx assay to determine patient eligibility for a novel gene therapy program. nAbCyte is an FDA-approved in vitro CDx device that detects neutralizing antibodies to the AAVRh74var capsid in serum specimens from patients previously diagnosed with hemophilia B. This case study illustrates how Labcorp worked with the client and regulatory agencies to overcome development hurdles with a customized approach combining scientific expertise, collaboration, strategic engagement and governance.